Least but not last: Durable C5 silencing for IgA nephropathy
Molecular Therapy · 2026-11 · 34 (11) · 6177-6178
DOI: 10.1016/j.ymthe.2026.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026-11. Verfasst von Davide D'Onghia und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology-Oncology, Beth Israel Deaco…. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Cancer R…
Förderung
- NIDDK NIH HHS
Zitieren
APA
D'Onghia, D., & Di Ruscio, A. (2026). Least but not last: Durable C5 silencing for IgA nephropathy. Molecular Therapy, 34(11), 6177-6178. https://doi.org/10.1016/j.ymthe.2026.10.005
Vancouver
D'Onghia D, Di Ruscio A. Least but not last: Durable C5 silencing for IgA nephropathy. Molecular Therapy. 2026;34(11):6177-6178. doi:10.1016/j.ymthe.2026.10.005
BibTeX
@article{DOnghia2026,
author = {D'Onghia, Davide and Di Ruscio, Annalisa},
title = {Least but not last: Durable C5 silencing for IgA nephropathy},
journal = {Molecular Therapy},
year = {2026},
volume = {34},
number = {11},
pages = {6177--6178},
doi = {10.1016/j.ymthe.2026.10.005}
}
EUVIMED